Praj Industries Ltd Q4 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/mahpea2k28rg2xgdyyid8a2m.pdf

Key Takeaways


Order Book & Demand Drivers

Joshipura: "Future is not what we have seen in the past. Future is very different than what we have seen, but it is very exciting. It is very big and therefore we believe that we will be in a position to see a completely different game play out, different segments will emerge."

New Technology Bets: SAF, PLA & CBG

Joshipura: "We are very confident that our technology will showcase that we are able to produce best in class performance. Having said that we need to wait till the proof of the pudding is there on the ground, which is not too far also."

International Markets: US Slowdown, Europe Conversations


Capacity Expansion & Capital Allocation


Margins & Mix


Guidance & Commitments

CommitmentSpecificsTimeline
CBG plant regular dispatchFirst rice-straw commercial plant to start regular CBG dispatchEnd of June 2023
Catalytic lab operationalNew lab at Praj Matrix R&D centerAugust 2023
Praj GenX commercial productionNew manufacturing facility near major port to begin commercial productionLast quarter of FY24
IOC joint venture functionalJV with Indian Oil for biofuels production to become functionalEnd of FY24
US project timeline shiftLow-carbon ethanol project finalization delayed2-3 quarters from Q4 FY23
PLA demo plantFirst-of-its-kind demo plant for Polylactic Acid at JejuriNo date given

Key Metrics

MetricQ4 FY23
Consolidated income from operations₹1,000 cr, compared to ₹800 cr in Q4 FY22
Profit before tax₹100 cr, compared to ₹71.8 cr in Q4 FY22
Profit after tax₹88.1 cr, compared to ₹57.6 cr in Q4 FY22
Full-year FY23 income from operations₹3,500 cr, compared to ₹2,300 cr in FY22
Full-year FY23 PAT₹230 cr, compared to ₹150 cr in FY22
Export revenue share17.4% of FY23 total revenue
Revenue mix73.8% Bioenergy, 19.3% Engineering, 6.9% PHS
Order intake₹1,000 cr, 76.5% domestic, 82.3% from bioenergy
Export order intake₹743 cr, 9% YoY growth from ₹679 cr last year
Order backlog₹3,400 cr, 84.7% domestic, 84% from bioenergy
Cash in hand₹691 cr as of 31st March 2023
Proposed final dividend₹4.50 per equity share, 225% of face value of ₹2 per share
Customer advances~₹700 cr
Receivable days83 days, reduced from 86 days in FY22
Output volume growth (equivalent units)Doubled from FY22 to FY23